An Open-Label, Randomized, Single-Dose, Multicenter, Parallel-Group Study to Compare the Pharmacokinetics of Subcutaneous Depemokimab When Delivered With a Safety Syringe Device or an Autoinjector in Healthy Adult Participants
Latest Information Update: 27 Mar 2025
At a glance
- Drugs Depemokimab (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 01 Mar 2025 Results published in the Clinical Pharmacology in Drug Development.
- 14 Jun 2024 Status changed from active, no longer recruiting to completed.
- 11 May 2023 Status changed from recruiting to active, no longer recruiting.